Personalized cell therapy takes on Hard-to-Treat tumors

NCT ID NCT07294872

Not yet recruiting Disease control Sponsor: Shanghai Juncell Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times

Summary

This early-stage trial tests a personalized cell therapy for adults with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a patient's own tumor, grow more of them in the lab, and then infuse them back after a short course of chemotherapy. The goal is to see if this approach is safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tumor-infiltrating lymphocytes (TIL)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 30 participants, so safety and effectiveness are not yet proven. The treatment involves intensive chemotherapy beforehand and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Sichuan Cancer Hospital & Institute, Sichuan Cancer Center

Chengdu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.